Search Results - "Benkert, Pascal"

Assessing the Relative Importance of Imaging and Serum Biomarkers in Capturing Disability, Cognitive Impairment, and Clinical Progression in Multiple Sclerosis.

Authors: Cagol, Alessandro Benkert, Pascal Schaedelin, Sabine et al.

Source: Advanced Science. 2/18/2026, Vol. 13 Issue 10, p1-15. 15p.

Synthesizing Cross-Design Evidence and Cross-Format Data Using Network Meta-Regression

Authors: Hamza, Tasnim Chalkou, Konstantina Pellegrini, Fabio et al.

Source: Research Synthesis Methods. Mar 2023 14(2):283-300.

Peer Reviewed: Y

Page Count: 18

Descriptors: Meta Analysis, Regression (Statistics), Outcomes of Treatment, Research Methodology, Bias, Diseases, Intervention

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

Authors: Maceski, Aleksandra Maleska Benkert, Pascal Einsiedler, Maximilian et al.

Source: Brain: A Journal of Neurology; Jul2026, Vol. 149 Issue 7, p2295-2307, 13p

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Hereditary Transthyretin Amyloidosis Polyneuropathy.

Authors: Loser, Valentin Benkert, Pascal Vicino, Alex et al.

Source: Journal of the Peripheral Nervous System. Mar2026, Vol. 31 Issue 1, p1-11. 11p.

Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis.

Authors: Fissolo, Nicolás Benkert, Pascal Vilaseca‐Jolonch, Andreu et al.

Source: European Journal of Neurology. Feb2026, Vol. 33 Issue 2, p1-4. 4p.

Subjects: Microglia, Multiple sclerosis, Biomarkers, Disease progression

Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis.

Authors: Moradi, Nahid Sharmin, Sifat Malpas, Charles B. et al.

Source: European Journal of Neurology. Feb2026, Vol. 33 Issue 2, p1-11. 11p.

Subjects: Biomarkers, Prediction models, Disease progression, Treatment effectiveness, Multiple sclerosis, Disease relapse, Therapeutics

Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin‐related amyloidosis—A Swiss reference center experience.

Authors: Loser, Valentin Benkert, Pascal Vicino, Alex et al.

Source: Journal of the Peripheral Nervous System. Mar2023, Vol. 28 Issue 1, p86-97. 12p.

Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study.

Authors: Yaldizli, Özgür Benkert, Pascal Achtnichts, Lutz et al.

Source: Multiple Sclerosis Journal. Jul2025, Vol. 31 Issue 8, p932-943. 12p.

Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis.

Authors: Benkert, Pascal Maleska Maceski, Aleksandra Schaedelin, Sabine et al.

Source: Annals of Neurology. Jan2025, Vol. 97 Issue 1, p104-115. 12p.

Comparative analysis of dimethyl fumarate and teriflunomide in relapsing–remitting multiple sclerosis.

Authors: Müller, Jannis Schädelin, Sabine Lorscheider, Johannes et al.

Source: European Journal of Neurology. Dec2023, Vol. 30 Issue 12, p3809-3818. 10p.

Subjects: Dimethyl fumarate, Multiple sclerosis, Proportional hazards models, Disease relapse, Comparative studies

This result is not displayed to guests.
Login for full access.

Serum neurofilament light chain cut‐off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis.

Authors: Brousse, Mehdi Delaby, Constance De La Cruz, Elisa et al.

Source: European Journal of Neurology. Jul2023, Vol. 30 Issue 7, p1919-1927. 9p.

Subjects: Amyotrophic lateral sclerosis, Motor neuron diseases, Cytoplasmic filaments, Monoclonal gammopathies, Neurological disorders, Prognosis

Geographic Terms: Montpellier (France)

Are neurofilament light chain levels ready for routine clinical use? – Yes.

Authors: Sandgren, Sofia Einsiedler, Maximilian Benkert, Pascal et al.

Source: Multiple Sclerosis Journal. Jun2026, Vol. 32 Issue 7, p670-673. 4p.

Diagnostic and prognostic value of blood neurofilament light chain in ischemic stroke: an individual patient data meta-analysis.

Authors: Barba, Lorenzo Romoli, Michele Benkert, Pascal et al.

Source: Journal of Neurology. Jun2026, Vol. 273 Issue 6, p1-14. 14p.

High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.

Authors: Buchmann, Arabella Pirpamer, Lukas Pinter, Daniela et al.

Source: European Journal of Neurology. May2023, Vol. 30 Issue 5, p1389-1399. 11p.

Subjects: Cerebral atrophy, Disabilities, Multiple sclerosis, Cytoplasmic filaments, Magnetic resonance imaging, People with disabilities, Monoclonal gammopathies

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.

Authors: Disanto, Giulio Benkert, Pascal Lorscheider, Johannes et al.

Source: PLoS ONE. 3/31/2016, Vol. 11 Issue 3, p1-13. 13p.

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.

Authors: Benkert, Pascal Meier, Stephanie Schaedelin, Sabine et al.

Source: Lancet Neurology. Mar2022, Vol. 21 Issue 3, p246-257. 12p.

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls.

Authors: Willemse, Eline A.J. Sandgren, Sofia Benkert, Pascal et al.

Source: Clinical Chemistry & Laboratory Medicine. Apr2026, Vol. 64 Issue 5, p1046-1053. 8p.

Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.

Authors: von Wyl, Viktor Benkert, Pascal Moser, André et al.

Source: Multiple Sclerosis Journal. Mar2021, Vol. 27 Issue 3, p439-448. 10p.

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis.

Authors: Lorscheider, Johannes Benkert, Pascal Lienert, Carmen et al.

Source: Journal of Neurology. Mar2021, Vol. 268 Issue 3, p941-949. 9p.